SFS
NBIX icon

Stiles Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

Stiles Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,150
Closed -$242K – 178
2023
Q3 		$242K Hold
2,150
– – 0.13% 155
2023
Q2 		$203K Hold
2,150
– – 0.1% 182
2023
Q1 		$218K Buy
+2,150
New +$224K 0.12% 166

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stiles Financial Services's NBIX Position: Q4 2023 in Review

Stiles Financial Services sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 2,150 shares — an estimated $242K sold.

Stiles Financial Services first reported a position in NBIX in Q1 2023 and held it in 3 quarters. The position peaked at $242K in Q3 2023. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • Stiles Financial Services reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
  • Stiles Financial Services sold 2,150 Neurocrine Biosciences shares in Q4 2023, an estimated $242K.
  • Stiles Financial Services first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 3 quarters.
  • Stiles Financial Services's Neurocrine Biosciences position peaked at $242K in Q3 2023.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Stiles Financial Services's 13F filing for Q4 2023, filed 26 Jan 2024.